PEPFAR's response to the convergence of the HIV and COVID-19 pandemics in Sub-Saharan Africa.
Acquired Immunodeficiency Syndrome
/ complications
Africa South of the Sahara
/ epidemiology
Betacoronavirus
COVID-19
China
Coronavirus Infections
/ complications
Cost of Illness
Delivery of Health Care
/ economics
HIV Infections
/ complications
Humans
International Cooperation
Pandemics
Pneumonia, Viral
/ complications
Prevalence
SARS-CoV-2
COVID-19
HIV care continuum
PEPFAR
SARS-CoV-2
readiness
response
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
05
2020
revised:
08
07
2020
accepted:
09
07
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
26
8
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic reached the African continent in less than three months from when the first cases were reported from mainland China. As COVID-19 preparedness and response plans were rapidly instituted across sub-Saharan Africa, many governments and donor organizations braced themselves for the unknown impact the COVID-19 pandemic would have in under-resourced settings with high burdens of PLHIV. The potential negative impact of COVID-19 in these countries is uncertain, but is estimated to contribute both directly and indirectly to the morbidity and mortality of PLHIV, requiring countries to leverage existing HIV care systems to propel COVID-19 responses, while safeguarding PLHIV and HIV programme gains. In anticipation of COVID-19-related disruptions, PEPFAR promptly established guidance to rapidly adapt HIV programmes to maintain essential HIV services while protecting recipients of care and staff from COVID-19. This commentary reviews PEPFAR's COVID-19 technical guidance and provides country-specific examples of programme adaptions in sub-Saharan Africa. The COVID-19 pandemic may pose significant risks to the continuity of HIV services, especially in countries with high HIV prevalence and weak and over-burdened health systems. Although there is currently limited understanding of how COVID-19 affects PLHIV, it is imperative that public health systems and academic centres monitor the impact of COVID-19 on PLHIV. The general principles of the HIV programme adaptation guidance from PEPFAR prioritize protecting the gains in the HIV response while minimizing in-person home and facility visits and other direct contact when COVID-19 control measures are in effect. PEPFAR-supported clinical, laboratory, supply chain, community and data reporting systems can play an important role in mitigating the impact of COVID-19 in sub-Saharan Africa. As community transmission of COVID-19 continues and the number of country cases rise, fragile health systems may be strained. Utilizing the adaptive, data-driven programme approaches in facilities and communities established and supported by PEPFAR provides the opportunity to strengthen the COVID-19 response while protecting the immense gains spanning HIV prevention, testing and treatment reached thus far.
Identifiants
pubmed: 32767707
doi: 10.1002/jia2.25587
pmc: PMC7405155
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25587Subventions
Organisme : United States Agency for International Development
Pays : International
Informations de copyright
Published 2020. This article is a U.S. Government work and is in the public domain in the USA. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
Références
J Int AIDS Soc. 2020 May;23(5):e25503
pubmed: 32378345
Clin Infect Dis. 2020 Nov 19;71(16):2233-2235
pubmed: 32270178
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Intensive Care Med. 2017 May;43(5):612-624
pubmed: 28349179
J Med Virol. 2020 Jun;92(6):529-530
pubmed: 32160316
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Med Virol. 2020 Oct;92(10):1774-1776
pubmed: 32285949
Emerg Infect Dis. 2016 Mar;22(3):433-41
pubmed: 26886846